abstract |
The present invention provides a combination therapy for effective treatment and/or prevention of diseases associated with cells expressing CLDN18.2, including cancer diseases, such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer , liver cancer, head and neck cancer and gallbladder cancer and their metastasis. |